Gossamer Bio (GOSS) AI Stock Analysis

• Market Cap: $96.15M
• Dividend Yield: N/A
• Average Volume (3M): 18.56M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.22
• Revenue Growth: -58.17%
• EPS Growth: -116.24%
• Country: US
• Employees: 144
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.21
• Shares Outstanding: 231,456,250
• 10 Day Avg. Volume: 45,287,646
• 30 Day Avg. Volume: 18,557,906
• PEG Ratio: 0.05
• Price to Book (P/B): 6.94
• Price to Sales (P/S): 1.78
• P/FCF Ratio: -59.01
• Enterprise Value/Market Cap: 3.05
• Enterprise Value/Revenue: 6.66
• Enterprise Value/Gross Profit: 6.66
• Enterprise Value/Ebitda: -2.01
• 1Y Price Target: $6.08
• Price Target Upside: 1420.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -0.56
• Revenue Forecast (FY): $43.23M

• Rating: 47 Neutral
• Price Target: $2.00 ▲(400.00% Upside)
• Action: Upgraded Date: 12/30/25
• Date: Action: Upgraded 12/30/25

The score is primarily held down by weak financial performance: large operating losses, significant cash burn, and negative equity alongside meaningful debt. Technicals are mixed but somewhat supportive longer-term due to price holding above key longer moving averages, while valuation remains constrained by ongoing losses and lack of dividend support.

Positive Factors

Modest revenue growth with positive gross profit

Sustained revenue growth and positive gross profit show the company can generate unit-level economics from some programs. Over 2–6 months this supports the case that development investments can translate into scalable revenue streams if clinical progress continues and commercialization planning advances.

Partnerships provide non-dilutive funding pathways

Existing collaboration model yields upfront, research funding, and milestone payments, which are durable funding mechanisms as programs advance. Partnerships also bring development/commercial expertise, lowering standalone execution risk and reducing sole dependence on equity raises for later-stage programs.

Focused therapeutic pipeline in specialty areas

A concentrated pipeline in immunology/inflammation and pulmonary hypertension targets high-unmet-need, specialty markets where clinical success can command premium pricing and partner interest. Strategic focus improves R&D efficiency and increases the odds of attracting durable commercial partnerships.

Negative Factors

High operating cash burn

Very large negative operating and free cash flow materially shorten runway and force recurring external financings. Over months this constrains R&D continuity, raises dilution risk, and limits bargaining power with partners or vendors, making long-term program execution more fragile.

Elevated leverage and deteriorated solvency

High debt and negative equity weaken the balance sheet, increase refinancing risk, and reduce financial flexibility. In a multi-month horizon this can force restrictive covenant terms, higher funding costs, or trade-offs that deprioritize certain programs, limiting strategic optionality.

Persistent deep net losses and no recurring product revenue

Large recurring losses and lack of commercial sales mean long-term viability hinges on binary clinical and regulatory outcomes. This structural revenue uncertainty increases capital dependence and execution risk over months, making progress and funding cadence central to company survival.

Gossamer Bio Business Overview & Revenue Model

Company Description

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

How the Company Makes Money

Gossamer Bio makes money primarily through the development and eventual commercialization of its proprietary therapeutic candidates. The company's revenue model is heavily reliant on the successful progression of its drug candidates through clinical trials, followed by regulatory approval and market entry. Key revenue streams include potential milestone payments, licensing agreements, and royalties from partnerships with larger pharmaceutical companies. Additionally, Gossamer Bio may generate income through strategic collaborations that provide funding for research and development activities, as well as potential future sales of approved drugs. The company's earnings are significantly influenced by the successful navigation of the regulatory landscape and the potential market demand for its therapies upon approval.

Gossamer Bio Financial Statement Overview

Summary

Despite modest TTM revenue growth (+9.5%) and positive gross profit, the company remains deeply unprofitable (TTM net loss -$156.2M) with heavy ongoing cash burn (TTM operating cash flow -$158.4M; FCF -$158.5M). The balance sheet adds risk with elevated debt (~$203M) and a shift to negative equity (TTM -$82.3M), reducing financial flexibility.

Income Statement

TTM (Trailing-Twelve-Months) revenue is $44.1M with positive growth (+9.5%), but profitability remains weak with a large net loss of -$156.2M and deeply negative margins, indicating the business is still heavily investment/R&D driven. While gross profit is positive, operating losses remain substantial versus the current revenue base, and results have been volatile (e.g., meaningful revenue in 2024 vs. $0 in 2021–2023), limiting earnings quality and visibility.

Balance Sheet

Leverage is elevated relative to the company’s capital base, with total debt around $203M. The balance sheet has deteriorated, moving from positive equity in 2024 ($29.5M) to negative equity in TTM (Trailing-Twelve-Months) (-$82.3M), which is a key solvency red flag and increases financial flexibility risk. Total assets also declined (2024: $315.3M to TTM: $208.8M), reinforcing the weakening capital position.

Cash Flow

Cash generation is the primary pressure point: TTM (Trailing-Twelve-Months) operating cash flow is -$158.4M and free cash flow is -$158.5M, implying a high ongoing cash burn. Cash flow also worsened materially versus 2024 (operating cash flow of -$3.5M), suggesting increased spending or reduced working-capital support. A positive note is that free cash flow broadly tracks net income (free cash flow to net income ~1.0), but both remain solidly negative, indicating limited self-funding capacity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	44.05M	114.70M	0.00	0.00	0.00	0.00
Gross Profit	44.05M	114.70M	0.00	0.00	0.00	-4.27M
EBITDA	-145.96M	-39.97M	-161.92M	-211.07M	-209.40M	-226.43M
Net Income	-156.16M	-56.53M	-179.82M	-229.38M	-234.00M	-243.36M
Balance Sheet
Total Assets	208.82M	315.29M	311.92M	272.45M	343.66M	539.43M
Cash, Cash Equivalents and Short-Term Investments	180.22M	294.52M	296.43M	255.68M	325.22M	512.63M
Total Debt	202.88M	202.88M	212.46M	225.74M	185.24M	183.73M
Total Liabilities	291.15M	285.80M	249.15M	260.37M	222.19M	218.75M
Stockholders Equity	-82.33M	29.49M	62.77M	12.08M	121.46M	320.68M
Cash Flow
Free Cash Flow	-158.51M	-3.47M	-159.16M	-187.51M	-190.51M	-201.24M
Operating Cash Flow	-158.43M	-3.47M	-159.16M	-187.03M	-188.89M	-176.36M
Investing Cash Flow	136.42M	29.02M	-110.97M	-1.03M	-117.43M	215.34M
Financing Cash Flow	2.47M	-11.49M	190.15M	117.09M	3.33M	312.54M

Gossamer Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GOSS, the sentiment is Negative. The current price of 0.4 is below the 20-day moving average (MA) of 1.94, below the 50-day MA of 2.53, and below the 200-day MA of 2.25, indicating a bearish trend. The MACD of -0.53 indicates Positive momentum. The RSI at 14.76 is Positive, neither overbought nor oversold. The STOCH value of 3.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GOSS.

Gossamer Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	62 Neutral	$921.73M	13.82	66.76%	―	-10.26%	144.62%
MBX	60 Neutral	$1.65B	-14.89	-24.43%	―	―	-44.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GOSS	47 Neutral	$96.15M	-0.55	―	―	-58.17%	-116.24%
SVRA	47 Neutral	$1.15B	-10.91	-78.74%	―	―	-22.39%